BioStock: Ultimovacs progresses to last cohort in TENDU study

Ultimovacs continues to progress with its phase I TENDU study testing the company’s TET cancer vaccine platform in prostate cancer patients. The company has announced moving on to its last of three patient cohorts after no safety concerns were found in the first two.

Read the article at biostock.se:

https://www.biostock.se/en/2022/02/ultimovacs-progresses-to-last-cohort-in-tendu-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se